ClinicalTrials.gg
CompletedNCT02807636IMvigor130Updated Feb 24, 2025Results posted

Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma

A Phase 3 interventional study of Atezolizumab and Carboplatin in Urothelial Carcinoma, sponsored by Hoffmann-La Roche. Completed at 204 sites in 35 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-24.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,213
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies testing atezolizumab in Carcinoma, Transitional Cell — 1 open to participants now, 4 under way, 1 of them phase 3. atezolizumab · Carcinoma, Transitional Cell.

Enrollment
Largest of 15
1,213 · median 32
Started
2016
with 3 others
Phase 3
3 of 15
none open now
Registered
4th of 15
by date
Lead sponsor
2 of 15
Hoffmann-La Roche

Among the 15 studies testing atezolizumab in Carcinoma, Transitional Cell, this one has the largest enrollment, is one of 4 that started in 2016, is one of 3 in phase 3, and was the 4th registered.

Carcinoma, Transitional Cell

632 studies on the registry are indexed under Carcinoma, Transitional Cell; 180 are open to participants now.

Browse Carcinoma, Transitional Cell studies →

Open to participants now

1 of the 15 studies testing atezolizumab in Carcinoma, Transitional Cell is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About atezolizumab

atezolizumab: first FDA approval 2016 (TECENTRIQ), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 147 Carcinoma, Transitional Cell studies recruiting now, 121 (82%) set no upper age limit and 11 (7%) stop at 75 or younger; 4 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing atezolizumab in Carcinoma, Transitional Cell, or all of them as a file.
02

Study summary

A Phase III, randomised study of atezolizumab alone and in combination with chemotherapy versus chemotherapy alone in participants with untreated advanced urothelial cancer.

03

Conditions studied

  • Urothelial Carcinoma

Keywords

  • Urothelial carcinoma
  • Bladder cancer
  • Anti-PD-L1
  • Transitional carcinoma
  • Tecentriq
  • Atezolizumab
  • IMvigor130
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Considered to be eligible to receive platinum-based chemotherapy, in the investigator's judgment
  • (ECOG) performance status of less than or equal to (\</=) 2
  • documented, locally advanced (T4b, any N; or any T, N2-3) or urothelial carcinoma (mUC) (M1, Stage IV) (also termed transitional cell carcinoma [TCC] or urothelial cell carcinoma [UCC] of the urinary tract; including renal pelvis, ureters, urinary bladder, and urethra)
  • Representative formalin-fixed paraffin-embedded (FFPE) tumor specimens in paraffin blocks (blocks preferred) or at least 15 unstained slides, with an associated pathology report, for central testing and determined to be evaluable for tumor expression prior to study enrollment; participants who have fewer than 15 unstained slides available at baseline (but no less than [\<] 10) may be eligible following discussion with the Medical Monitor
  • No prior chemotherapy for inoperable locally advanced or mUC
  • For participants who received prior /neoadjuvant chemotherapy or chemo-radiation for urothelial carcinoma, a treatment-free interval more than (>) 12 months between the last treatment administration and the date of recurrence is required in order to be considered treatment naive in the metastatic setting
  • Prior local intravesical chemotherapy or immunotherapy is allowed if completed at least 4 weeks prior to the initiation of study treatment
  • , as defined by v1.1
  • Adequate hematologic and end-organ function
  • For women of : agreement to remain abstinent (refrain from heterosexual intercourse) or use methods that result in a failure rate of \<1% per year during the treatment period and for at least 6 months after the last dose of carboplatin, cisplatin, or gemcitabine or for 5 months after the last dose of atezolizumab
  • For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures and agreement to refrain from donating sperm

Exclusion criteria

Exclusion Criteria:

  • Any approved anti-cancer therapy, including chemotherapy or hormonal therapy, within 3 weeks prior to initiation of study treatment
  • Treatment with any other agent or participation in another clinical study with therapeutic intent within 28 days prior to enrolment
  • Active or untreated as determined by computed tomography (CT) or magnetic resonance imaging evaluation during screening and prior radiographic assessments
  • Participants with treated asymptomatic central nervous system (CNS) are eligible, provided they meet all of the following criteria: * Evaluable or outside the CNS * No metastases to midbrain, pons, medulla, or within 10 mm of the optic apparatus (optic nerves and chiasm) * No history of intracranial or spinal cord hemorrhage * No ongoing requirement for as therapy for CNS disease; anti-convulsants at a stable dose are allowed * No evidence of significant vasogenic edema * No stereotactic radiation, whole-brain radiation or neurosurgical resection within 4 weeks prior to Cycle 1, Day 1 * Radiographic demonstration of interim stability (i.e., no progression) between the completion of CNS-directed therapy and the screening radiographic study * Screening CNS radiographic study >/=4 weeks since completion of radiotherapy or surgical resection and >/=2 weeks since discontinuation of corticosteroids
  • Prior treatment with CD137 agonists, , anti-programmed death-1 (PD-1), or anti-PD-L1 therapeutic antibody or pathway-targeting agents
  • Treatment with systemic corticosteroids or other systemic medications (including but not limited to prednisone, dexamethasone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor [TNF] agents) within 2 weeks prior to Cycle 1, Day 1 or anticipated requirement for systemic immunosuppressive medications during the study
  • Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (once monthly or more frequently)
  • Uncontrolled tumour-related pain or hypercalcemia
  • Significant cardiovascular disease including known (LVEF) \<40%
  • Severe infections within 4 weeks before randomization or therapeutic oral or IV antibiotics within 2 weeks before randomization
  • Major surgical procedure within 4 weeks prior to randomization or anticipation of need for a major surgical procedure during the course of the study other than for diagnosis
  • other than urothelial carcinoma within 5 years prior to Cycle 1, Day 1
  • of \<12 weeks
  • Pregnant or lactating, or intending to become pregnant during the study
  • Serum albumin \<25 gram per liter (g/L)
  • History of severe allergic, anaphylactic, or other reactions to chimeric or humanized antibodies or fusion proteins
  • Known hypersensitivity or allergy to biopharmaceuticals produced in Chinese hamster ovary cells or any component of the atezolizumab formulation
  • History of disease
  • Participants with prior allogeneic stem cell or solid organ transplantation
  • History of idiopathic pulmonary fibrosis (including pneumonitis), drug-induced pneumonitis, organizing pneumonia (i.e., bronchiolitis obliterans, cryptogenic organizing pneumonia), or evidence of active pneumonitis on screening chest CT scan
  • Positive test for (HIV)
  • Active or
  • Active tuberculosis
  • Administration of a live, attenuated vaccine within 4 weeks before Cycle 1, Day 1
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
1,213 participants (actual)

Study arms

  • Experimental
    Atezolizumab+Gemcitabine+Carboplatin/Cisplatin

    Participants will receive blinded atezolizumab in combination with open-label platinum-based chemotherapy (gemcitabine with either cisplatin or carboplatin).

    Drug: Atezolizumab · Drug: Carboplatin · Drug: Gemcitabine · Drug: Cisplatin

  • Placebo comparator
    Placebo+Gemcitabine+Carboplatin/Cisplatin

    Participants will receive blinded placebo matched to atezolizumab in combination with open-label platinum-based chemotherapy (gemcitabine with either cisplatin or carboplatin).

    Drug: Carboplatin · Drug: Gemcitabine · Other: Placebo · Drug: Cisplatin

  • Experimental
    Atezolizumab Monotherapy

    Eligible participants will receive open-label atezolizumab as monotherapy.

    Drug: Atezolizumab

Interventions

  • Atezolizumab will be administered at a fixed dose of 1200 milligrams (mg) by intravenous (IV) infusion on Day 1 of each 21-day cycle until investigator-assessed disease progression per RECIST v1.1. In specific circumstances treatment may continue beyond disease progression.

    Also known as: Tecentriq

  • Carboplatin will be administered at doses to achieve area under the concentration-time curve (AUC) of 4.5 milligram per milliliter into minute (mg/mL\*min) by IV infusion on Day 1 of each 21-day cycle until investigator-assessed disease progression per RECIST v1.1 or unacceptable toxicity.

  • Gemcitabine will be administered at a dose of 1000 milligrams per square meter (mg/m\^2) by IV infusion on Day 1 and Day 8 of each 21-day cycle, until investigator-assessed disease progression per RECIST v1.1 or unacceptable toxicity.

  • OtherPlacebo

    Placebo matched to atezolizumab will be administered by IV infusion on Day 1 of each 21-day cycle until investigator-assessed disease progression per RECIST v1.1. In specific circumstances treatment may continue beyond disease progression.

  • Cisplatin will be administered at a dose of 70 mg/m\^2 by IV infusion on Day 1 of each 21-day cycle until investigator-assessed disease progression per RECIST v1.1 or unacceptable toxicity.

06

What researchers measure

Primary outcomes

  1. Investigator Assessed Progression-Free Survival (PFS) in the Placebo+Gemcitabine+Carboplatin/Cisplatin Arm Versus Atezolizumab +Gemcitabine+Carboplatin/Cisplatin Arm

    PFS is defined as the time from randomization to the first documented disease progression as determined by the investigator with the use of RECIST v1.1, or death from any cause, whichever occurs first.

    Time frame: Baseline up to first documented disease progression or death, whichever occurs first (up to approximately 35 months)

  2. Overall Survival (OS) in Atezolizumab+Gemcitabine+Carboplatin/Cisplatin Arm Versus Placebo+Gemcitabine+Carboplatin/Cisplatin Arm

    OS is defined as the time from randomization to death due to any cause.

    Time frame: Baseline until death due to any cause (up to approximately 73 months)

  3. Overall Survival (OS) in Atezolizumab Monotherapy Arm Versus Placebo+Gemcitabine+Carboplatin/Cisplatin Arm

    OS is defined as the time from randomization to death due to any cause.

    Time frame: Baseline until death due to any cause (up to approximately 73 months)

Secondary outcomes

  1. Objective Response Rate (ORR) in Atezolizumab+Gemcitabine+Carboplatin/Cisplatin Arm Versus Placebo+Gemcitabine+Carboplatin/Cisplatin Arm

    Objective response rate (ORR) is defined as the proportion of participants with a confirmed objective response, either complete response (CR) or partial response (PR), observed on two assessments \>= 28 days apart per RECIST v1.1, based on investigator assessment. The analysis population for ORR will be all randomized participants with measurable disease at baseline.

    Time frame: Baseline up to disease progression, death, or loss of follow-up, whichever occurs first (up to approximately 73 months)

  2. Objective Response Rate (ORR) in Atezolizumab Monotherapy Arm Versus Placebo+Gemcitabine+Carboplatin/Cisplatin Arm

    Objective response rate (ORR) is defined as the proportion of participants with a confirmed objective response, either complete response (CR) or partial response (PR), observed on two assessments \>= 28 days apart per RECIST v1.1, based on investigator assessment. The analysis population for ORR will be all randomized participants with measurable disease at baseline.

    Time frame: Baseline up to disease progression, death, or loss of follow-up, whichever occurs first (up to approximately 73 months)

  3. Duration of Response (DOR) in Atezolizumab+Gemcitabine+Carboplatin/Cisplatin Arm Versus Placebo+Gemcitabine+Carboplatin/Cisplatin Arm

    Duration of response (DOR) is defined for participants with an objective response as the time from the first documented objective response to documented disease progression per RECIST v1.1, based on investigator assessment, or death due to any cause, whichever occurs first.

    Time frame: From first documented objective response (CR or PR) to disease progression, death, or loss of follow-up, whichever occurs first (up to approximately 73 months)

  4. Duration of Response (DOR) in Atezolizumab Monotherapy Arm Versus Placebo+Gemcitabine+Carboplatin/Cisplatin Arm

    Duration of response (DOR) is defined for participants with an objective response as the time from the first documented objective response to documented disease progression per RECIST v1.1, based on investigator assessment, or death due to any cause, whichever occurs first.

    Time frame: From first documented objective response (CR or PR) to disease progression, death, or loss of follow-up, whichever occurs first (up to approximately 73 months)

  5. IRF-PFS

    Independent review facility PFS (IRF-PFS) is defined as the time from randomization to the first documented disease progression as determined by blinded independent central review with use of RECIST v1.1, or death due to any cause, whichever occurs first.

    Time frame: Randomization to first documented disease progression or death from any cause (up to 35 months)

  6. OS Event Free Rate Atezolizumab+Gemcitabine+Carboplatin/Cisplatin Arm Versus Placebo+Gemcitabine+Carboplatin/Cisplatin Arm

    Overall Survival (OS) Event Free Rate at 1 Year.

    Time frame: Year 1

  7. OS Event Free Rate in Atezolizumab Monotherapy Arm Versus Placebo+Gemcitabine+Carboplatin/Cisplatin Arm

    Overall Survival (OS) Event Free Rate at 1 Year.

    Time frame: Year 1

  8. PFS Event Free Rate

    Progression Free Survival (PFS) Event Free Rate at Year 1

    Time frame: Year 1

  9. Time to Deterioration in Global Health Status as Measured by the EORTC QLQ-C30 Score in the Placebo+Gemcitabine+Carboplatin/Cisplatin Arm Versus Atezolizumab +Gemcitabine+Carboplatin/Cisplatin Arm

    Time to deterioration in global health status as measured by the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 in the Placebo+Gemcitabine+Carboplatin/Cisplatin Arm versus Atezolizumab +Gemcitabine+Carboplatin/Cisplatin Arm.

    Time frame: Up to approximately 73 months

  10. Time to Deterioration in Global Health Status as Measured by the EORTC QLQ-C30 Score in the Placebo+Gemcitabine+Carboplatin/Cisplatin Arm Versus Atezolizumab Monotherapy Arm

    Time to deterioration in global health status as measured by the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 in the Placebo+Chemo Arm versus Atezolizumab Monotherapy Arm.

    Time frame: Up to approximately 73 months

  11. Time to Deterioration in Physical Function as Measured by the EORTC QLQ-C30 Score in the Placebo+Gemcitabine+Carboplatin/Cisplatin Arm Versus Atezolizumab +Gemcitabine+Carboplatin/Cisplatin Arm

    Median time to deterioration in physical function as measured by the QLQ-C30 in the Placebo+Gemcitabine+Carboplatin/Cisplatin Arm versus Atezolizumab +Gemcitabine+Carboplatin/Cisplatin Arm.

    Time frame: Up to approximately 73 months

  12. Time to Deterioration in Physical Function as Measured by the EORTC QLQ-C30 Score in the Placebo+Gemcitabine+Carboplatin/Cisplatin Arm Versus Atezolizumab Monotherapy Arm

    Median time to deterioration in physical function as measured by the QLQ-C30 in the Placebo+Gemcitabine+Carboplatin/Cisplatin Arm versus Atezolizumab Monotherapy Arm.

    Time frame: Up to approximately 73 months

  13. Maximum Atezolizumab Serum Concentration

    Maximum atezolizumab serum concentration.

    Time frame: Cycle 1 Day 1

  14. Minimum Atezolizumab Serum Concentration

    Minimum atezolizumab serum concentration.

    Time frame: Cycle 2 Day 1, Cycle 3 Day 1, Cycle 4 Day 1, Cycle 8 Day 1, Cycle 16 Day 1, Cycle 24 Day 1, Cycle 32 Day 1, Day 120 post dose of last blinded atezolizumab treatment, and study drug early discontinuation

  15. Percentage of Participants With Anti-Therapeutic (Anti-Atezolizumab) Antibodies (ATAs)

    Percentage of participants with Anti-Therapeutic (Anti-Atezolizumab) Antibodies (ATAs).

    Time frame: Up to approximately 35 months

  16. Investigator-Assessed Progression-Free Survival (INV-PFS) in Participants Treated With Atezolizumab Monotherapy Arm Compared With Placebo+Gemcitabine+Carboplatin/Cisplatin Arm

    PFS is defined as the time from randomization to the first documented disease progression as determined by the investigator with the use of RECIST v1.1, or death from any cause, whichever occurs first.

    Time frame: Baseline up to disease progression, death, or loss of follow-up, whichever occurs first (assessed at baseline, every 9 weeks for 54 weeks and every 12 weeks thereafter up to 35 months)

  17. Percentage of Participants With Grade 3-4 Adverse Events (AEs)

    Percentage of participants with Grade 3-4 Adverse Events (AEs) assessed using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.0.

    Time frame: Baseline up to 93 months

  18. Percentage of Participants With Grade 5 Adverse Events (AEs)

    Percentage of participants with Grade 5 Adverse Events (AEs) assessed using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.0.

    Time frame: Baseline up to 93 months

  19. Percentage of Participants With Serious Adverse Events (SAEs)

    Percentage of participants with Serious Adverse Events (SAEs) assessed using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.0.

    Time frame: Baseline up to 93 months

  20. Percentage of Participants With Adverse Events (AEs) Leading to Withdrawal of Any Study Treatment

    Percentage of participants with Adverse Events (AEs) leading to withdrawal of any study treatment assessed Using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.0.

    Time frame: Baseline up to 93 months

  21. Percentage of Participants With Atezolizumab-Specific Adverse Events of Special Interest (AESIs)

    Percentage of participants with atezolizumab-specific Adverse Events of Special Interest (AESIs) Using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.0.

    Time frame: Baseline up to 93 months

07

Results

Posted Dec 13, 2023

Participant flow

Participants were enrolled in 221 sites in 35 countries.

Participant flow — Overall Study
MilestonePlacebo+Gemcitabine+Carboplatin/CisplatinAtezolizumab+Gemcitabine+Carboplatin/CisplatinAtezolizumab Monotherapy
Started400451362
Completed000
Not completed400451362
Withdrew: Lost to follow-up10136
Withdrew: Protocol deviation100
Withdrew: Symptomatic deterioration010
Withdrew: Withdrawal by subject392824
Withdrew: Death303332272
Withdrew: Study terminated by sponsor477660
Withdrew: Physician decision010

Outcome measures

PrimaryInvestigator Assessed Progression-Free Survival (PFS) in the Placebo+Gemcitabine+Carboplatin/Cisplatin Arm Versus Atezolizumab +Gemcitabine+Carboplatin/Cisplatin Arm

PFS is defined as the time from randomization to the first documented disease progression as determined by the investigator with the use of RECIST v1.1, or death from any cause, whichever occurs first.

Time frame:
Baseline up to first documented disease progression or death, whichever occurs first (up to approximately 35 months)
Reported as:
Median · Months
Investigator Assessed Progression-Free Survival (PFS) in the Placebo+Gemcitabine+Carboplatin/Cisplatin Arm Versus Atezolizumab +Gemcitabine+Carboplatin/Cisplatin Arm
MonthsPlacebo+Gemcitabine+Carboplatin/CisplatinAtezolizumab+Gemcitabine+Carboplatin/Cisplatin
Investigator Assessed Progression-Free Survival (PFS) in the Placebo+Gemcitabine+Carboplatin/Cisplatin Arm Versus Atezolizumab +Gemcitabine+Carboplatin/Cisplatin Arm6.34 (6.24 to 7.00)8.18 (6.51 to 8.34)
Statistical analysis
  • Placebo+Gemcitabine+Carboplatin/Cisplatin vs Atezolizumab+Gemcitabine+Carboplatin/Cisplatin · Log Rank · p = 0.0073 (inverse normal combination) · Hazard ratio (hr): 0.82 · 95% CI 0.70 to 0.96
PrimaryOverall Survival (OS) in Atezolizumab+Gemcitabine+Carboplatin/Cisplatin Arm Versus Placebo+Gemcitabine+Carboplatin/Cisplatin Arm

OS is defined as the time from randomization to death due to any cause.

Time frame:
Baseline until death due to any cause (up to approximately 73 months)
Reported as:
Median · Months
Overall Survival (OS) in Atezolizumab+Gemcitabine+Carboplatin/Cisplatin Arm Versus Placebo+Gemcitabine+Carboplatin/Cisplatin Arm
MonthsPlacebo+Gemcitabine+Carboplatin/CisplatinAtezolizumab+Gemcitabine+Carboplatin/Cisplatin
Overall Survival (OS) in Atezolizumab+Gemcitabine+Carboplatin/Cisplatin Arm Versus Placebo+Gemcitabine+Carboplatin/Cisplatin Arm13.44 (11.99 to 15.34)16.13 (14.19 to 18.76)
Statistical analysis
  • Placebo+Gemcitabine+Carboplatin/Cisplatin vs Atezolizumab+Gemcitabine+Carboplatin/Cisplatin · Regression, Cox · p = 0.0230 (one-sided, inverse normal combination) · Hazard ratio (hr): 0.85 · 95% CI 0.73 to 1.0
PrimaryOverall Survival (OS) in Atezolizumab Monotherapy Arm Versus Placebo+Gemcitabine+Carboplatin/Cisplatin Arm

OS is defined as the time from randomization to death due to any cause.

Time frame:
Baseline until death due to any cause (up to approximately 73 months)
Reported as:
Median · Months
Overall Survival (OS) in Atezolizumab Monotherapy Arm Versus Placebo+Gemcitabine+Carboplatin/Cisplatin Arm
MonthsPlacebo+Gemcitabine+Carboplatin/CisplatinAtezolizumab Monotherapy
Overall Survival (OS) in Atezolizumab Monotherapy Arm Versus Placebo+Gemcitabine+Carboplatin/Cisplatin Arm13.34 (11.89 to 15.61)15.21 (13.14 to 17.68)
Statistical analysis
  • Placebo+Gemcitabine+Carboplatin/Cisplatin vs Atezolizumab Monotherapy · Log Rank · p = 0.3968 · Hazard ratio (hr): 0.98 · 95% CI 0.82 to 1.16one-sided
SecondaryObjective Response Rate (ORR) in Atezolizumab+Gemcitabine+Carboplatin/Cisplatin Arm Versus Placebo+Gemcitabine+Carboplatin/Cisplatin Arm

Objective response rate (ORR) is defined as the proportion of participants with a confirmed objective response, either complete response (CR) or partial response (PR), observed on two assessments \>= 28 days apart per RECIST v1.1, based on investigator assessment. The analysis population for ORR will be all randomized participants with measurable disease at baseline.

Time frame:
Baseline up to disease progression, death, or loss of follow-up, whichever occurs first (up to approximately 73 months)
Reported as:
Number · Percentage of Participants
Objective Response Rate (ORR) in Atezolizumab+Gemcitabine+Carboplatin/Cisplatin Arm Versus Placebo+Gemcitabine+Carboplatin/Cisplatin Arm
Percentage of ParticipantsPlacebo+Gemcitabine+Carboplatin/CisplatinAtezolizumab+Gemcitabine+Carboplatin/Cisplatin
Objective Response Rate (ORR) in Atezolizumab+Gemcitabine+Carboplatin/Cisplatin Arm Versus Placebo+Gemcitabine+Carboplatin/Cisplatin Arm44.8 (39.87 to 49.88)48.1 (43.38 to 52.84)
SecondaryObjective Response Rate (ORR) in Atezolizumab Monotherapy Arm Versus Placebo+Gemcitabine+Carboplatin/Cisplatin Arm

Objective response rate (ORR) is defined as the proportion of participants with a confirmed objective response, either complete response (CR) or partial response (PR), observed on two assessments \>= 28 days apart per RECIST v1.1, based on investigator assessment. The analysis population for ORR will be all randomized participants with measurable disease at baseline.

Time frame:
Baseline up to disease progression, death, or loss of follow-up, whichever occurs first (up to approximately 73 months)
Reported as:
Number · Percentage of Participants
Objective Response Rate (ORR) in Atezolizumab Monotherapy Arm Versus Placebo+Gemcitabine+Carboplatin/Cisplatin Arm
Percentage of ParticipantsPlacebo+Gemcitabine+Carboplatin/CisplatinAtezolizumab Monotherapy
Objective Response Rate (ORR) in Atezolizumab Monotherapy Arm Versus Placebo+Gemcitabine+Carboplatin/Cisplatin Arm44.4 (39.15 to 49.71)24.2 (19.89 to 29.01)
SecondaryDuration of Response (DOR) in Atezolizumab+Gemcitabine+Carboplatin/Cisplatin Arm Versus Placebo+Gemcitabine+Carboplatin/Cisplatin Arm

Duration of response (DOR) is defined for participants with an objective response as the time from the first documented objective response to documented disease progression per RECIST v1.1, based on investigator assessment, or death due to any cause, whichever occurs first.

Time frame:
From first documented objective response (CR or PR) to disease progression, death, or loss of follow-up, whichever occurs first (up to approximately 73 months)
Reported as:
Number · Months
Duration of Response (DOR) in Atezolizumab+Gemcitabine+Carboplatin/Cisplatin Arm Versus Placebo+Gemcitabine+Carboplatin/Cisplatin Arm
MonthsPlacebo+Gemcitabine+Carboplatin/CisplatinAtezolizumab+Gemcitabine+Carboplatin/Cisplatin
Duration of Response (DOR) in Atezolizumab+Gemcitabine+Carboplatin/Cisplatin Arm Versus Placebo+Gemcitabine+Carboplatin/Cisplatin Arm8.15 (6.34 to 8.61)9.13 (8.02 to 10.64)
SecondaryDuration of Response (DOR) in Atezolizumab Monotherapy Arm Versus Placebo+Gemcitabine+Carboplatin/Cisplatin Arm

Duration of response (DOR) is defined for participants with an objective response as the time from the first documented objective response to documented disease progression per RECIST v1.1, based on investigator assessment, or death due to any cause, whichever occurs first.

Time frame:
From first documented objective response (CR or PR) to disease progression, death, or loss of follow-up, whichever occurs first (up to approximately 73 months)
Reported as:
Number · Months
Duration of Response (DOR) in Atezolizumab Monotherapy Arm Versus Placebo+Gemcitabine+Carboplatin/Cisplatin Arm
MonthsPlacebo+Gemcitabine+Carboplatin/CisplatinAtezolizumab Monotherapy
Duration of Response (DOR) in Atezolizumab Monotherapy Arm Versus Placebo+Gemcitabine+Carboplatin/Cisplatin Arm8.11 (6.28 to 8.54)29.63 (15.90 to NA)
SecondaryIRF-PFS

Independent review facility PFS (IRF-PFS) is defined as the time from randomization to the first documented disease progression as determined by blinded independent central review with use of RECIST v1.1, or death due to any cause, whichever occurs first.

Time frame:
Randomization to first documented disease progression or death from any cause (up to 35 months)
Reported as:
Number · Months
IRF-PFS
MonthsPlacebo+Gemcitabine+Carboplatin/CisplatinAtezolizumab+Gemcitabine+Carboplatin/Cisplatin
IRF-PFS6.34 (6.24 to 8.05)7.10 (6.31 to 8.25)
Statistical analysis
  • Placebo+Gemcitabine+Carboplatin/Cisplatin vs Atezolizumab+Gemcitabine+Carboplatin/Cisplatin · Regression, Cox · p = 0.0373 (inverse normal combination) · Hazard ratio (hr): 0.86 · 95% CI 0.73 to 1.01
SecondaryOS Event Free Rate Atezolizumab+Gemcitabine+Carboplatin/Cisplatin Arm Versus Placebo+Gemcitabine+Carboplatin/Cisplatin Arm

Overall Survival (OS) Event Free Rate at 1 Year.

Time frame:
Year 1
Reported as:
Number · Percentage
OS Event Free Rate Atezolizumab+Gemcitabine+Carboplatin/Cisplatin Arm Versus Placebo+Gemcitabine+Carboplatin/Cisplatin Arm
PercentagePlacebo+Gemcitabine+Carboplatin/CisplatinAtezolizumab+Gemcitabine+Carboplatin/Cisplatin
OS Event Free Rate Atezolizumab+Gemcitabine+Carboplatin/Cisplatin Arm Versus Placebo+Gemcitabine+Carboplatin/Cisplatin Arm55.00 (49.98 to 60.02)60.00 (55.39 to 64.61)
Statistical analysis
  • Placebo+Gemcitabine+Carboplatin/Cisplatin vs Atezolizumab+Gemcitabine+Carboplatin/Cisplatin · Z-test · p = 0.1509 · Difference in event free rate: 5.00 · 95% CI -1.82 to 11.81
SecondaryOS Event Free Rate in Atezolizumab Monotherapy Arm Versus Placebo+Gemcitabine+Carboplatin/Cisplatin Arm

Overall Survival (OS) Event Free Rate at 1 Year.

Time frame:
Year 1
Reported as:
Number · Percentage
OS Event Free Rate in Atezolizumab Monotherapy Arm Versus Placebo+Gemcitabine+Carboplatin/Cisplatin Arm
PercentagePlacebo+Gemcitabine+Carboplatin/CisplatinAtezolizumab Monotherapy
OS Event Free Rate in Atezolizumab Monotherapy Arm Versus Placebo+Gemcitabine+Carboplatin/Cisplatin Arm54.56 (49.23 to 59.88)57.91 (52.72 to 63.10)
Statistical analysis
  • Placebo+Gemcitabine+Carboplatin/Cisplatin vs Atezolizumab Monotherapy · Z-test · p = 0.3761 · Difference in event free rate: 3.36 · 95% CI -4.08 to 10.79
SecondaryPFS Event Free Rate

Progression Free Survival (PFS) Event Free Rate at Year 1

Time frame:
Year 1
Reported as:
Number · Percentage
PFS Event Free Rate
PercentagePlacebo+Gemcitabine+Carboplatin/CisplatinAtezolizumab+Gemcitabine+Carboplatin/Cisplatin
PFS Event Free Rate22.17 (17.93 to 26.42)30.47 (26.00 to 34.93)
Statistical analysis
  • Placebo+Gemcitabine+Carboplatin/Cisplatin vs Atezolizumab+Gemcitabine+Carboplatin/Cisplatin · Z-test · p = 0.0083 · Difference in event free rate: -8.29 · 95% CI -14.45 to -2.13
SecondaryTime to Deterioration in Global Health Status as Measured by the EORTC QLQ-C30 Score in the Placebo+Gemcitabine+Carboplatin/Cisplatin Arm Versus Atezolizumab +Gemcitabine+Carboplatin/Cisplatin Arm

Time to deterioration in global health status as measured by the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 in the Placebo+Gemcitabine+Carboplatin/Cisplatin Arm versus Atezolizumab +Gemcitabine+Carboplatin/Cisplatin Arm.

Time frame:
Up to approximately 73 months
Reported as:
Median · Months
Time to Deterioration in Global Health Status as Measured by the EORTC QLQ-C30 Score in the Placebo+Gemcitabine+Carboplatin/Cisplatin Arm Versus Atezolizumab +Gemcitabine+Carboplatin/Cisplatin Arm
MonthsPlacebo+Gemcitabine+Carboplatin/CisplatinAtezolizumab+Gemcitabine+Carboplatin/Cisplatin
Time to Deterioration in Global Health Status as Measured by the EORTC QLQ-C30 Score in the Placebo+Gemcitabine+Carboplatin/Cisplatin Arm Versus Atezolizumab +Gemcitabine+Carboplatin/Cisplatin Arm12.06 (8.28 to 20.24)32.07 (18.40 to NA)
Statistical analysis
  • Placebo+Gemcitabine+Carboplatin/Cisplatin vs Atezolizumab+Gemcitabine+Carboplatin/Cisplatin · Log Rank · p = 0.0542 · Hazard ratio (hr): 0.80 · 95% CI 0.64 to 1.00
SecondaryTime to Deterioration in Global Health Status as Measured by the EORTC QLQ-C30 Score in the Placebo+Gemcitabine+Carboplatin/Cisplatin Arm Versus Atezolizumab Monotherapy Arm

Time to deterioration in global health status as measured by the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 in the Placebo+Chemo Arm versus Atezolizumab Monotherapy Arm.

Time frame:
Up to approximately 73 months
Reported as:
Median · Months
Time to Deterioration in Global Health Status as Measured by the EORTC QLQ-C30 Score in the Placebo+Gemcitabine+Carboplatin/Cisplatin Arm Versus Atezolizumab Monotherapy Arm
MonthsPlacebo+Gemcitabine+Carboplatin/CisplatinAtezolizumab Monotherapy
Time to Deterioration in Global Health Status as Measured by the EORTC QLQ-C30 Score in the Placebo+Gemcitabine+Carboplatin/Cisplatin Arm Versus Atezolizumab Monotherapy Arm12.02 (8.08 to 20.24)23.20 (8.31 to NA)
Statistical analysis
  • Placebo+Gemcitabine+Carboplatin/Cisplatin vs Atezolizumab Monotherapy · Log Rank · p = 0.6139 · Hazard ratio (hr): 0.94 · 95% CI 0.74 to 1.19
SecondaryTime to Deterioration in Physical Function as Measured by the EORTC QLQ-C30 Score in the Placebo+Gemcitabine+Carboplatin/Cisplatin Arm Versus Atezolizumab +Gemcitabine+Carboplatin/Cisplatin Arm

Median time to deterioration in physical function as measured by the QLQ-C30 in the Placebo+Gemcitabine+Carboplatin/Cisplatin Arm versus Atezolizumab +Gemcitabine+Carboplatin/Cisplatin Arm.

Time frame:
Up to approximately 73 months
Reported as:
Median · Months
Time to Deterioration in Physical Function as Measured by the EORTC QLQ-C30 Score in the Placebo+Gemcitabine+Carboplatin/Cisplatin Arm Versus Atezolizumab +Gemcitabine+Carboplatin/Cisplatin Arm
MonthsPlacebo+Gemcitabine+Carboplatin/CisplatinAtezolizumab+Gemcitabine+Carboplatin/Cisplatin
Time to Deterioration in Physical Function as Measured by the EORTC QLQ-C30 Score in the Placebo+Gemcitabine+Carboplatin/Cisplatin Arm Versus Atezolizumab +Gemcitabine+Carboplatin/Cisplatin Arm15.74 (8.28 to 22.57)16.39 (9.07 to 26.68)
Statistical analysis
  • Placebo+Gemcitabine+Carboplatin/Cisplatin vs Atezolizumab+Gemcitabine+Carboplatin/Cisplatin · Log Rank · p = 0.5540 · Hazard ratio (hr): 1.07 · 95% CI 0.86 to 1.32
SecondaryTime to Deterioration in Physical Function as Measured by the EORTC QLQ-C30 Score in the Placebo+Gemcitabine+Carboplatin/Cisplatin Arm Versus Atezolizumab Monotherapy Arm

Median time to deterioration in physical function as measured by the QLQ-C30 in the Placebo+Gemcitabine+Carboplatin/Cisplatin Arm versus Atezolizumab Monotherapy Arm.

Time frame:
Up to approximately 73 months
Reported as:
Median · Months
Time to Deterioration in Physical Function as Measured by the EORTC QLQ-C30 Score in the Placebo+Gemcitabine+Carboplatin/Cisplatin Arm Versus Atezolizumab Monotherapy Arm
MonthsPlacebo+Gemcitabine+Carboplatin/CisplatinAtezolizumab Monotherapy
Time to Deterioration in Physical Function as Measured by the EORTC QLQ-C30 Score in the Placebo+Gemcitabine+Carboplatin/Cisplatin Arm Versus Atezolizumab Monotherapy Arm16.10 (8.08 to 22.57)9.23 (6.24 to 17.48)
Statistical analysis
  • Placebo+Gemcitabine+Carboplatin/Cisplatin vs Atezolizumab Monotherapy · Log Rank · p = 0.0241 · Hazard ratio (hr): 1.29 · 95% CI 1.03 to 1.62
SecondaryMaximum Atezolizumab Serum Concentration

Maximum atezolizumab serum concentration.

Time frame:
Cycle 1 Day 1
Reported as:
Mean · μg/ mL
Maximum Atezolizumab Serum Concentration
μg/ mLAtezolizumab+Gemcitabine+Carboplatin/CisplatinAtezolizumab Monotherapy
Maximum Atezolizumab Serum Concentration379 ± 125390 ± 129
SecondaryMinimum Atezolizumab Serum Concentration

Minimum atezolizumab serum concentration.

Time frame:
Cycle 2 Day 1, Cycle 3 Day 1, Cycle 4 Day 1, Cycle 8 Day 1, Cycle 16 Day 1, Cycle 24 Day 1, Cycle 32 Day 1, Day 120 post dose of last blinded atezolizumab treatment, and study drug early discontinuation
Reported as:
Mean · μg/ mL
Minimum Atezolizumab Serum Concentration
μg/ mLAtezolizumab+Gemcitabine+Carboplatin/CisplatinAtezolizumab Monotherapy
Cycle 2 Day 179.8 ± 52.580.2 ± 46.0
Cycle 3 Day 1122 ± 47.2129 ± 66.0
Cycle 4 Day 1153 ± 70.4157 ± 63.4
Cycle 8 Day 1216 ± 96.8193 ± 79.8
Cycle 16 Day 1235 ± 103220 ± 79.8
Cycle 24 Day 1244 ± 75.7233 ± 92.5
Cycle 32 Day 1259 ± 97.2258 ± 60.5
Day 120 Post Dose of Last Blinded Atezo Trt18.8 ± 36.99.53 ± 12.7
Study Drug Early Discontinuation154 ± 102124 ± 83.8
SecondaryPercentage of Participants With Anti-Therapeutic (Anti-Atezolizumab) Antibodies (ATAs)

Percentage of participants with Anti-Therapeutic (Anti-Atezolizumab) Antibodies (ATAs).

Time frame:
Up to approximately 35 months
Reported as:
Number · Percentage of participants
Percentage of Participants With Anti-Therapeutic (Anti-Atezolizumab) Antibodies (ATAs)
Percentage of participantsAtezolizumab+Gemcitabine+Carboplatin/CisplatinAtezolizumab Monotherapy
Baseline evaluable participants1.20.9
Post-baseline evaluable participants19.726.3
SecondaryInvestigator-Assessed Progression-Free Survival (INV-PFS) in Participants Treated With Atezolizumab Monotherapy Arm Compared With Placebo+Gemcitabine+Carboplatin/Cisplatin Arm

PFS is defined as the time from randomization to the first documented disease progression as determined by the investigator with the use of RECIST v1.1, or death from any cause, whichever occurs first.

Time frame:
Baseline up to disease progression, death, or loss of follow-up, whichever occurs first (assessed at baseline, every 9 weeks for 54 weeks and every 12 weeks thereafter up to 35 months)
Reported as:
Median · Months
Investigator-Assessed Progression-Free Survival (INV-PFS) in Participants Treated With Atezolizumab Monotherapy Arm Compared With Placebo+Gemcitabine+Carboplatin/Cisplatin Arm
MonthsPlacebo+Gemcitabine+Carboplatin/CisplatinAtezolizumab Monotherapy
Investigator-Assessed Progression-Free Survival (INV-PFS) in Participants Treated With Atezolizumab Monotherapy Arm Compared With Placebo+Gemcitabine+Carboplatin/Cisplatin Arm6.31 (6.24 to 6.74)2.69 (2.20 to 4.04)
Statistical analysis
  • Placebo+Gemcitabine+Carboplatin/Cisplatin vs Atezolizumab Monotherapy · Log Rank · p = 1.0000 · Hazard ratio (hr): 1.42 · 95% CI 1.19 to 1.69
SecondaryPercentage of Participants With Grade 3-4 Adverse Events (AEs)

Percentage of participants with Grade 3-4 Adverse Events (AEs) assessed using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.0.

Time frame:
Baseline up to 93 months
Reported as:
Number · Percentage of Participants
Percentage of Participants With Grade 3-4 Adverse Events (AEs)
Percentage of ParticipantsAtezolizumab+Gemcitabine+Carboplatin/CisplatinPlacebo+Gemcitabine+Carboplatin/CisplatinAtezolizumab Monotherapy
Percentage of Participants With Grade 3-4 Adverse Events (AEs)84.184.646.3
SecondaryPercentage of Participants With Grade 5 Adverse Events (AEs)

Percentage of participants with Grade 5 Adverse Events (AEs) assessed using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.0.

Time frame:
Baseline up to 93 months
Reported as:
Number · Percentage of Participants
Percentage of Participants With Grade 5 Adverse Events (AEs)
Percentage of ParticipantsAtezolizumab+Gemcitabine+Carboplatin/CisplatinPlacebo+Gemcitabine+Carboplatin/CisplatinAtezolizumab Monotherapy
Percentage of Participants With Grade 5 Adverse Events (AEs)7.55.77.9
SecondaryPercentage of Participants With Serious Adverse Events (SAEs)

Percentage of participants with Serious Adverse Events (SAEs) assessed using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.0.

Time frame:
Baseline up to 93 months
Reported as:
Number · Percentage of Participants
Percentage of Participants With Serious Adverse Events (SAEs)
Percentage of ParticipantsAtezolizumab+Gemcitabine+Carboplatin/CisplatinPlacebo+Gemcitabine+Carboplatin/CisplatinAtezolizumab Monotherapy
Percentage of Participants With Serious Adverse Events (SAEs)53.750.646.0
SecondaryPercentage of Participants With Adverse Events (AEs) Leading to Withdrawal of Any Study Treatment

Percentage of participants with Adverse Events (AEs) leading to withdrawal of any study treatment assessed Using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.0.

Time frame:
Baseline up to 93 months
Reported as:
Number · Percentage of Participants
Percentage of Participants With Adverse Events (AEs) Leading to Withdrawal of Any Study Treatment
Percentage of ParticipantsAtezolizumab+Gemcitabine+Carboplatin/CisplatinPlacebo+Gemcitabine+Carboplatin/CisplatinAtezolizumab Monotherapy
Percentage of Participants With Adverse Events (AEs) Leading to Withdrawal of Any Study Treatment36.333.99.0
SecondaryPercentage of Participants With Atezolizumab-Specific Adverse Events of Special Interest (AESIs)

Percentage of participants with atezolizumab-specific Adverse Events of Special Interest (AESIs) Using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.0.

Time frame:
Baseline up to 93 months
Reported as:
Number · Percentage of Participants
Percentage of Participants With Atezolizumab-Specific Adverse Events of Special Interest (AESIs)
Percentage of ParticipantsAtezolizumab+Gemcitabine+Carboplatin/CisplatinPlacebo+Gemcitabine+Carboplatin/CisplatinAtezolizumab Monotherapy
Percentage of Participants With Atezolizumab-Specific Adverse Events of Special Interest (AESIs)53.335.539.5

Adverse events

Collected over From the first study drug to the data cutoff date: 9 April 2024 (up to approximately 93 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo+Gemcitabine+Carboplatin/Cisplatin303/389 (77.9%)197/389 (50.6%)379/389 (97.4%)
Atezolizumab+Gemcitabine+Carboplatin/Cisplatin332/454 (73.1%)244/454 (53.7%)441/454 (97.1%)
Atezolizumab Monotherapy272/354 (76.8%)163/354 (46%)300/354 (84.7%)
Most frequent serious events
Showing 10 of 305
Most frequent serious events
EventPlacebo+Gemcitabine+Carboplatin/CisplatinAtezolizumab+Gemcitabine+Carboplatin/CisplatinAtezolizumab Monotherapy
Urinary tract infectionInfections and infestations30/38941/45422/354
AnaemiaBlood and lymphatic system disorders19/38930/4544/354
ThrombocytopeniaBlood and lymphatic system disorders22/38921/4541/354
PneumoniaInfections and infestations8/38921/4548/354
PyrexiaGeneral disorders12/38918/4549/354
HaematuriaRenal and urinary disorders10/38910/45413/354
Acute kidney injuryRenal and urinary disorders12/38915/4548/354
Platelet count decreasedInvestigations12/38914/4540/354
Febrile neutropeniaBlood and lymphatic system disorders9/38914/4540/354
Renal failureRenal and urinary disorders2/3893/4548/354
Most frequent other events
Showing 10 of 50
Most frequent other events
EventPlacebo+Gemcitabine+Carboplatin/CisplatinAtezolizumab+Gemcitabine+Carboplatin/CisplatinAtezolizumab Monotherapy
AnaemiaBlood and lymphatic system disorders257/389308/45468/354
NeutropeniaBlood and lymphatic system disorders148/389215/4542/354
NauseaGastrointestinal disorders181/389202/45443/354
ThrombocytopeniaBlood and lymphatic system disorders117/389183/45412/354
Platelet count decreasedInvestigations138/389132/4545/354
Neutrophil count decreasedInvestigations129/389119/4540/354
Decreased appetiteMetabolism and nutrition disorders119/389144/45469/354
FatigueGeneral disorders122/389134/45464/354
ConstipationGastrointestinal disorders111/389140/45467/354
AstheniaGeneral disorders98/389134/45451/354

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Placebo+Gemcitabine+Carboplatin/CisplatinAtezolizumab+Gemcitabine+Carboplatin/CisplatinAtezolizumab MonotherapyTotal
Mean66.4 ± 9.567.5 ± 9.767.0 ± 9.167.0 ± 9.4
Sex: Female, Male
Sex: Female, Male(Participants)Placebo+Gemcitabine+Carboplatin/CisplatinAtezolizumab+Gemcitabine+Carboplatin/CisplatinAtezolizumab MonotherapyTotal
Female10211382297
Male298338280916
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo+Gemcitabine+Carboplatin/CisplatinAtezolizumab+Gemcitabine+Carboplatin/CisplatinAtezolizumab MonotherapyTotal
Hispanic or Latino444140125
Not Hispanic or Latino3504023111063
Unknown or Not Reported681125
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Placebo+Gemcitabine+Carboplatin/CisplatinAtezolizumab+Gemcitabine+Carboplatin/CisplatinAtezolizumab MonotherapyTotal
American Indian or Alaska Native3429
Asian859094269
Native Hawaiian or Other Pacific Islander0011
Black or African American0617
White305346260911
More than one race0011
Unknown or Not Reported75315
08

Study locations

204 sites
  • Highlands Oncology Group
    Rogers, Arkansas 72758, United States
  • Coastal Integrative Cancer Care
    San Luis Obispo, California 93401, United States
  • Yale School of Medicine
    New Haven, Connecticut 06520-8032, United States
  • Norwalk Hospital
    Norwalk, Connecticut 06856, United States
  • Christina Care Institutional Review Board
    Newark, Delaware 19713, United States
  • Florida Cancer Specialists
    Fort Myers, Florida 33916, United States
  • UF Health Cancer Center at Orlando Health
    Orlando, Florida 32824, United States
  • Florida Cancer Specialists (St. Petersburg ? St. Anthony?s Professional Building)
    Saint Petersburg, Florida 33705, United States
  • Moffitt Cancer Center
    Tampa, Florida 33612, United States
  • Parkview Research Center
    Fort Wayne, Indiana 46845, United States
  • Norton Cancer Institute
    Louisville, Kentucky 40402, United States
  • East Jefferson Hematology Oncology
    Metairie, Louisiana 70006, United States
  • Park Nicollet Clin-Cancer Ctr
    Saint Louis Park, Minnesota 55426, United States
  • Comprehensive Cancer Centers of Nevada
    Las Vegas, Nevada 89148, United States
  • Mount Sinai School of Medicine - Tisch Cancer Institute
    New York, New York 10029, United States
  • University of North Carolina, Lineberger Cancer Ctr
    Chapel Hill, North Carolina 27599, United States
  • Bon Secours - St. Francis Hospital
    Greenville, South Carolina 29607, United States
  • Sarah Cannon Research Institute / Tennessee Oncology
    Nashville, Tennessee 37203, United States
  • Macquarie University Hospital
    Macquarie University, New South Wales 2109, Australia
  • Royal Brisbane and Women's Hospital
    Herston, Queensland 4029, Australia
  • Lyell McEwin Hospital
    Adelaide, South Australia 5112, Australia
  • Box Hill Hospital
    Box Hill, Victoria 3128, Australia
  • Cabrini Medical Centre
    Malvern, Victoria 3144, Australia
  • Sunshine Hospital
    St Albans, Victoria DUMMY_VALUE, Australia
  • GHdC Site Notre Dame
    Charleroi, B6000, Belgium
  • AZ Sint Lucas (Sint Lucas)
    Gent, 9000, Belgium
  • UZ Leuven Gasthuisberg
    Leuven, 3000, Belgium
  • CHC MontLégia
    Liege, 4000, Belgium
  • Clinical center University of Sarajevo
    Sarajevo, 71000, Bosnia and Herzegovina
  • CETUS Hospital Dia Oncologia
    Belo Horizonte, Minas Gerais 30110022, Brazil
  • Hospital Luxemburgo
    Belo Horizonte, Minas Gerais 31190-131, Brazil
  • Oncosite - Centro de Pesquisa Clinica Em Oncologia Ltda
    Ijui, Rio Grande Do Sul 98700-000, Brazil
  • Hospital das Clinicas - UFRGS
    Porto Alegre, Rio Grande Do Sul 90035-903, Brazil
  • Hospital Nossa Senhora da Conceicao
    Porto Alegre, Rio Grande Do Sul 91350-200, Brazil
  • Clinica Viver
    Santa Maria, Rio Grande Do Sul 97015-450, Brazil
  • Clinica de Neoplasias Litoral
    Itajai, Santa Catarina 88301-220, Brazil
  • Hospital de Base de Sao Jose do Rio Preto
    Sao Jose do Rio Preto, São Paulo 15090-000, Brazil
  • Instituto do Cancer do Estado de Sao Paulo - ICESP
    Sao Paulo, São Paulo 01246-000, Brazil
  • Beneficencia Portuguesa de Sao Paulo
    Sao Paulo, São Paulo 01323-900, Brazil
  • Clinicas Oncologicas Integradas - COI
    Rio de Janeiro, 22793-080, Brazil
  • Arthur J.E. Child Comprehensive Cancer Center-Calgary
    Calgary, Alberta T2N 4N2, Canada
  • Cross Cancer Institute
    Edmonton, Alberta T6G 1Z2, Canada
  • BC Cancer Agency, CSI
    Kelowna, British Columbia V1Y 5L3, Canada
  • Dr. Georges L. Dumont University Hospital Centre
    Moncton, New Brunswick E1C8X3, Canada
  • Juravinski Cancer Clinic
    Hamilton, Ontario L8V 5C2, Canada
  • Lakeridge Health Center
    Oshawa, Ontario L1G 2B9, Canada
  • North York General Hospital
    Toronto, Ontario M2K 1E1, Canada
  • Bradford Hill Centro de Investigaciones Clinicas
    Recoleta, 8420383, Chile
  • OrlandiOncología
    Santiago, 7500713, Chile
  • Fundacion Arturo Lopez Perez
    Santiago, Providencia, Chile
  • Clinica Alemana
    Vitacura, 0, Chile
  • Beijing Friendship Hospital
    Beijing, 100050, China
  • Peking Union Medical College Hospital
    Beijing, 100730, China
  • Chongqing Cancer Hospital
    Chongqing, 400030, China
  • Sun Yat-sen Memorial Hospital
    Guangzhou, 510000, China
  • Jiangsu Cancer Hospital
    Nanjing, 210009, China
  • Fudan University Shanghai Cancer Center
    Shanghai, 200032, China
  • Zhongshan Hospital Fudan University
    Shanghai, 200032, China
  • Huadong Hospital Affiliated to Fudan University
    Shanghai, 200040, China
  • The 2nd Hospital of Tianjin Medical University
    Tianjin, 201203, China
  • Masarykuv onkologicky ustav
    Brno, 656 53, Czechia
  • Fakultni nemocnice Olomouc
    Olomouc, 779 00, Czechia
  • Vseobecna fakultni nemocnice v Praze
    Praha 2, 128 08, Czechia
  • University Hospital Motol
    Praha 5, 15006, Czechia
  • East Tallinn Central Hospital
    Tallinn, 10138, Estonia
  • North Estonia Medical Centre Foundation
    Tallinn, 13419, Estonia
  • Oulu University Hospital
    Oulu, 90029, Finland
  • Turku Uni Central Hospital
    Turku, 20520, Finland
  • Research institute for Clinical Medicine
    Tbilisi, 0112, Georgia
  • National Center of Urology
    Tbilisi, 0144, Georgia
  • Alexandras General Hospital of Athens
    Athens, 11528, Greece
  • University Hospital of Patras Medical Oncology
    Patras, 265 04, Greece
  • Princess Margaret Hospital
    Hong Kong, DUMMY_VALUE, Hong Kong
  • Queen Elizabeth Hospital
    Hong Kong, DUMMY_VALUE, Hong Kong
  • Queen Mary Hospital
    Hong Kong, DUMMY_VALUE, Hong Kong
  • The Chinese University of Hong Kong
    Hong Kong, DUMMY_VALUE, Hong Kong
  • Rambam Health Care Campus
    Haifa, 3109601, Israel
  • Azienda Ospedaliera A. Cardarelli
    Napoli, Campania 80131, Italy
  • IRST Istituto Scientifico Romagnolo Per Lo Studio E Cura Dei Tumori, Sede Meldola
    Meldola, Emilia-Romagna 47014, Italy
  • A.O. Universitaria Policlinico Di Modena
    Modena, Emilia-Romagna 41100, Italy
  • Policlinico Umberto i di Roma
    Roma, Lazio 00161, Italy
  • Az. Osp. Uni Ria San Martino
    Genova, Liguria 16132, Italy
  • Irccs Istituto Nazionale Dei Tumori (Int)
    Milano, Lombardia 20133, Italy
  • Istituto Clinico Humanitas
    Rozzano, Lombardia 20089, Italy
  • A.O CITTA' DELLA SALUTE E DELLA SCIENZA D. - Presidio San Lazzaro
    Torino, Piemonte 10126, Italy
  • IRCCS Ospedale Casa Sollievo Della Sofferenza
    San Giovanni Rotondo, Puglia 71013, Italy
  • Azienda USL8 Arezzo-Presidio Ospedaliero 1 San Donato
    Arezzo, Toscana 52100, Italy
  • Azienda Ospedaliera S. Maria - Terni
    Terni, Umbria 05100, Italy
  • IRCCS Istituto Oncologico Veneto (IOV)
    Padova, Veneto 35128, Italy
  • Nagoya University Hospital
    Aichi, 466-8560, Japan
  • Hirosaki University Hospital
    Aomori, 036-8563, Japan
  • National Hospital Organization Shikoku Cancer Center
    Ehime, 791-0280, Japan
  • Gunma University Hospital
    Gunma, 371-8511, Japan
  • National Hospital Organization Hokkaido Cancer Center
    Hokkaido, 003-0804, Japan
  • University of Tsukuba Hospital
    Ibaraki, 305-8576, Japan
  • Kanazawa University Hospital
    Ishikawa, 920-8641, Japan
  • Kumamoto University Hospital
    Kumamoto, 860-8556, Japan
  • Niigata University Medical & Dental Hospital
    Niigata, 951-8520, Japan
  • Osaka Metropolitan University Hospital
    Osaka, 545-8586, Japan
  • Kindai University Hospital
    Osaka, 589-8511, Japan

Showing the first 100 of 204 sites across 35 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Galsky MD, Arija JAA, Bamias A, Davis ID, De Santis M, Kikuchi E, Garcia-Del-Muro X, De Giorgi U, Mencinger M, Izumi K, Panni S, Gumus M, Ozguroglu M, Kalebasty AR, Park SH, Alekseev B, Schutz FA, Li JR, Ye D, Vogelzang NJ, Bernhard S, Tayama D, Mariathasan S, Mecke A, Thastrom A, Grande E; IMvigor130 Study Group. Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet. 2020 May 16;395(10236):1547-1557. doi: 10.1016/S0140-6736(20)30230-0. PubMed 32416780 ↗
  • Balar AV, Galsky MD, Rosenberg JE, Powles T, Petrylak DP, Bellmunt J, Loriot Y, Necchi A, Hoffman-Censits J, Perez-Gracia JL, Dawson NA, van der Heijden MS, Dreicer R, Srinivas S, Retz MM, Joseph RW, Drakaki A, Vaishampayan UN, Sridhar SS, Quinn DI, Duran I, Shaffer DR, Eigl BJ, Grivas PD, Yu EY, Li S, Kadel EE 3rd, Boyd Z, Bourgon R, Hegde PS, Mariathasan S, Thastrom A, Abidoye OO, Fine GD, Bajorin DF; IMvigor210 Study Group. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet. 2017 Jan 7;389(10064):67-76. doi: 10.1016/S0140-6736(16)32455-2. Epub 2016 Dec 8. Erratum In: Lancet. 2017 Aug 26;390(10097):848. doi: 10.1016/S0140-6736(17)32213-4. PubMed 27939400 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2016 to primary completion in Aug 2022, 74 months.

Results were first posted in Dec 2023, 1 year 3 months after primary completion.

Of 28 phase 3 interventional studies under Carcinoma, Transitional Cell, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 111. This study's 74 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 17, 2016
First posted
Jun 21, 2016
StartActual
Jun 30, 2016
Primary completionActual
Aug 31, 2022
CompletionActual
Feb 12, 2024
Results first posted
Dec 13, 2023
Last update
Feb 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02807636
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Jun 21, 2016
Start date
Jun 30, 2016
Primary completion
Aug 31, 2022
Completion
Feb 12, 2024
Results posted
Dec 13, 2023
Last update
Feb 24, 2025

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Atezolizumab · Carboplatin · Gemcitabine · Cisplatin

Start the discussion